Financial Performance - Q2 2025 - Net sales reached $60 billion, a 102% increase compared to the same period last year[12] - Gross profit was $12 billion, up by 49%, but the gross profit margin decreased by 100 basis points to 208%[12] - Operating income decreased by 30% to $420 million, while non-GAAP operating income increased by 18% to $520 million[12] - Net income decreased by 35% to $271 million, but non-GAAP net income per diluted share increased by 39% to $260[12] Sales by Channel - Q2 2025 - Corporate sales increased by 176% to $25815 million[13] - Small Business sales increased by 126% to $4313 million[13] - Healthcare sales increased significantly by 241% to $7285 million[13] - Education sales experienced a decline of 109%, reaching $9067 million[13] Liquidity and Cash Flow - Total debt was $56327 million as of June 30, 2025[16] - Free cash flow for the quarter was $1334 million, and adjusted free cash flow was $2101 million[18] - The company returned $515 million year-to-date to shareholders through share repurchases and dividends[19] 2025 Outlook - The company anticipates U S IT growth plus a premium target of approximately 200 to 300 basis points[21] - The company expects low-to-mid single-digit growth in gross profit[21] - The company projects low-single-digit growth in non-GAAP net income per diluted share[21]

Financial Performance - Q3 FY25 revenue reached $3.6 billion, a 2% increase compared to $3.49 billion in Q3 FY24[43] - Adjusted EBITDA for Q3 FY25 was $274 million, up 7% from $257 million in Q3 FY24[43] - Adjusted Diluted EPS increased to $0.56 in Q3 FY25, compared to $0.51 in Q3 FY24[43] - Free Cash Flow for Q3 FY25 was $100 million[13] Business Development and Backlog - Backlog remained strong at $45 billion[13] - The company secured a Space Force Range Contract worth $4 billion, although it is currently under protest and not included in the backlog[22] - The company received multiple intelligence awards totaling over $500 million[24] - On-contract growth modifications and extensions provided a $2+ billion benefit in bookings[25] Debt and Deleveraging - Net leverage reduced to 3.5x, driven by operating and investing activity contributions[12, 52] - The company targets net leverage of less than 3x by FY26 year-end[54] - The company has $738 million in cash on hand and an $850 million undrawn revolving credit facility[57] Guidance - The company raised its FY25 organic revenue guidance to $13.975 - $14.175 billion[12, 58] - The company anticipates interest expense of $345M - $355M and capital expenditures of $35M - $40M for FY25[66] Nuclear Market - The global nuclear market demand is projected to reach $91 billion by FY2026 and $68 billion by FY2030[33] - The company's total addressable market in the nuclear sector is expected to more than double by 2035, reaching ~$20 billion[40]

Financial Performance - Consolidated net sales increased by approximately 1% year-over-year to ~$3.7 billion in Q3 FY25[11] - Adjusted EBITDA increased by $24 million year-over-year to $226 million in Q3 FY25, with a margin increase of 60 bps[11, 12] - Free cash flow was $115 million in Q3 FY25[11] - The company returned $50 million to shareholders through share repurchases in Q3, bringing the year-to-date total to $75 million, representing approximately 4% of shares outstanding[11, 12] - Adient is raising its FY25 revenue and EBITDA guidance[12] Regional Performance - Americas sales outperformed the market by 300 bps due to favorable volume/mix and full run-rate of key programs[32] - EMEA sales underperformed the broader market mainly due to customer mix and intentional portfolio actions[32] - Asia sales growth outpaced the broader market by 700 bps, driven by customer launches reaching full production volumes[32] Debt and Capital Structure - Cash balance was $860 million as of June 30, 2025[11] - Gross debt was approximately $2.4 billion and net debt was approximately $1.5 billion[11] - Net leverage ratio on a trailing twelve-month basis is 1.7x, within the targeted range of 1.5x-2.0x[44] Outlook - Consolidated revenue is expected to be approximately $14.4 billion[46] - Adjusted EBITDA is expected to be approximately $875 million[46] - Capital expenditures are expected to be approximately $150 million-$170 million[46]

Financial Performance - Net sales for Q2 2025 were $330.3 million [8], a decrease of 4.4% compared to $345.5 million in Q2 2024 [44] - Adjusted EBITDA for Q2 2025 was $33.7 million [8], an increase of 22.1% compared to $27.6 million in Q2 2024 [44] - Adjusted EBITDA margin for Q2 2025 was 10.2% [8], an increase of 220 bps compared to 8.0% in Q2 2024 [44] - Adjusted EPS for Q2 2025 was $0.88 [8], an increase of 44.3% compared to $0.61 in Q2 2024 [44] - Free cash flow was $9.0 million in Q2 2025 [8], representing 53.9% of net income [8] Segment Performance - Infrastructure Solutions net sales for Q2 2025 were $204.6 million [47], a decrease of 7.6% compared to $221.4 million in Q2 2024 [47] - Infrastructure Solutions segment operating adjusted EBITDA margin for Q2 2025 was 15.7% [47], an increase of 340 bps compared to 12.3% in Q2 2024 [47] - Materials Solutions net sales for Q2 2025 were $125.7 million [50], an increase of 1.3% compared to $124.1 million in Q2 2024 [50] - Materials Solutions segment operating adjusted EBITDA margin for Q2 2025 was 11.3% [50], an increase of 310 bps compared to 8.2% in Q2 2024 [50] Backlog and Orders - The backlog level is $380.8 million [8]

Financial Performance - Q2 2025 revenues reached $49.8 million, driven by systems sales and AIC, but below the midpoint of guidance due to consumables and service headwinds[10, 21] - The adjusted EBITDA margin was -2.3%[10] - Non-GAAP gross margin decreased to 46.3% in Q2 2025, compared to 48.6% in Q2 2024, primarily due to a lower portion of consumables revenue in the sales mix[24, 25] - Non-GAAP operating expenses decreased to $26.7 million in Q2 2025 from $28 million in Q2 2024[27] - Cash, deposits, and marketable securities were approximately $489 million at the end of Q2 2025[31] Market Dynamics - Impressions grew 4.7% year-over-year to 222.7 million, with strong double-digit growth from top customers in DTG and R2R[11, 37] - Annual recurring revenue from AIC grew to $18.9 million[10, 39] Future Outlook - The company expects low single-digit growth in H2[15] - Q3 2025 revenues are expected to be in the range of $49 million to $55 million, with an adjusted EBITDA margin between -3% and 3%[33]

Financial Performance - Q2 2025 sales increased by 26% to $386.9 million compared to $307.2 million in Q1 2025[34] - Adjusted EBITDA improved significantly from $(26.8) million in Q1 2025 to $21.6 million in Q2 2025[34] - Adjusted EBITDA margin increased from (9)% in Q1 2025 to 6% in Q2 2025[34] - Adjusted diluted EPS improved from $(0.20) in Q1 2025 to $(0.08) in Q2 2025[34] - The company generated positive operating cash flow of $15.6 million in Q2 2025 compared to $19.4 million in Q1 2025[44] Market and Operations - The company withdrew guidance due to uncertainty and limited visibility in the market[12, 50] - Silicon metal revenue increased 24% to $130 million in Q2 2025[38] - Silicon-based alloys revenue increased 23% to $112 million in Q2 2025[41] - Manganese-based alloys revenue increased 43% to $106 million in Q2 2025[43] Strategic Outlook - The company expects EU safeguards and the U S silicon metal trade cases to improve 2026 results[12]

Pipeline Progress - Pilavapadin 10 mg consistently delivered clinically meaningful pain reduction in Phase 2 trials[8] - Lexicon plans to present full Phase 2 results for Pilavapadin in September 2025 and partnership discussions are ongoing[5] - IND-enabling studies of LX9851 are on track to be completed in 2025[5] - Accelerated site initiations are underway for the Phase 3 SONATA-HCM study of sotagliflozin in HCM[5] Sotagliflozin in HCM - Approximately 1.1 million people in the U S have either obstructive or non-obstructive HCM[15] - 30% of HCM patients are diagnosed with oHCM and 70% are diagnosed with nHCM[16] - The SONATA-HCM Phase 3 study is evaluating sotagliflozin 400 mg versus placebo in 500 patients with oHCM and nHCM[22] - Enrollment in the SONATA-HCM Phase 3 study is accelerating, with all sites expected to be active by the end of Q3 2025[23] Financial Performance - Lexicon reported $28.9 million in total revenues for Q2 2025, including $1.3 million in net product revenues and $27.5 million in licensing revenue[30] - The $27.5 million in licensing revenue includes an upfront payment for the exclusive licensing agreement of LX9851 with Novo Nordisk[31] - Total operating expenses for 2025 are now expected to be between $105 million and $115 million[33]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

Financial Performance - The company's net investment income (NII) per share was $0.47, resulting in an annualized NII yield on book value of 10.7%[15] - Net income per share was $0.37, equating to an annualized return on book value of 8.3%[15] - The net asset value (NAV) per share decreased slightly to $17.56 as of June 30, 2025, compared to $17.64 as of March 31, 2025[15] - The Board of Directors declared a dividend of $0.42 per share for the third quarter of 2025, along with an additional dividend of $0.03 per share[15] Portfolio Composition and Activity - The total investment portfolio at fair value reached $2,501.8 million, primarily consisting of senior secured, floating-rate loans[15] - Gross investment fundings amounted to $529.6 million, while net investment fundings were $27.3 million[15] - The investment portfolio is diversified across 185 portfolio companies operating in 29 different industries[15] - The weighted average yield at amortized cost on the investment portfolio was 11.4%[15] - Investments on non-accrual represented 1.7% of the total investment portfolio at amortized cost and 0.6% at fair value[15] Liquidity and Funding - The company reported strong liquidity totaling $796 million, including $592 million of undrawn capacity on a revolving credit facility[15] - Unsecured debt represents 61% of the total debt outstanding at quarter-end[15]

Company Strategy & Performance - Chimera Investment Corp is a hybrid mortgage REIT focused on diversified investment solutions across the mortgage credit product spectrum[10, 13] - The company reported earnings available for distribution of $039 per share[19] - Book value per share was $2091, a 12% decrease from the previous quarter[22] - Economic return for the quarter was 05%[19, 22] HomeXpress Acquisition - Chimera entered into a definitive agreement to acquire HomeXpress Mortgage Corp, expected to close in Q4 2025[11, 21, 22] - The acquisition consideration includes cash equal to HomeXpress's book value plus a $120 million premium and 2,077,151 shares of CIM common stock[22] - HomeXpress has originated over $107 billion in loans since 2016[25, 27] - HomeXpress generated $47 million in pre-tax earnings in 2024[27] Portfolio Composition & Activity - The company purchased $19 billion in notional Agency pass-throughs, with an additional $402 million settling in Q3[22] - Recourse leverage increased to 18x from 12x in Q1 due to growth in Agency RMBS allocation[22] - Loans under third-party asset management grew 43% year-over-year to $254 billion[57, 58]